RATIONALE FOR CANCER TARGET:

• LILRB1, LILRB2 (receptors) and HLA-G (ligand) are immune checkpoint factors that play a role in human immunosuppressive pathways^1,2
• These receptors are expressed on myeloid cells in the tumor microenvironment (TME) and are upregulated in various cancers³
• LILRB1 is also expressed on various innate and adaptive immune cells including NK cells, B-cells and a subset of cytolytic T-cells^1,4
• LILRB1 and LILRB2 mediate immune suppression, and their blockade may activate both innate and adaptive immune responses, including natural killer (NK) and CD8+ T-cell tumor cell killing, and macrophage phagocytosis of tumor cells⁵

^OVERVIEW

• PF-07826390 is a humanized bispecific IgG1 that targets the leukocyte Immunoglobulin-like receptors B1 and B2 (LILRB1 and LILRB2)⁶